Announced
Completed
Financials
Sources
Tags
Single Bidder
United States
biotechnology
biopharma
Private Equity
health care
Private
Venture Capital
Domestic
Friendly
Minority
Biotechnology
Completed
Acquisition
Synopsis
Khosla Ventures, a venture capital firm, led a $43m Series B round iin Bionaut Labs, a company that uses microscale robots to revolutionize the treatment of central nervous system diseases, with participation from Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace, Gaingels, Upfront Ventures, BOLD Capital Partners, Revolution VC, and Compound. “There has been a dearth of innovation around treatments for conditions that cause tremendous suffering, in large part because past failures have discouraged even the best of researchers. Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough,” Michael Shpigelmacher, Bionaut Labs Co-Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.